Cerus Corp (CERS) — SEC Filings
Cerus Corp (CERS) — 31 SEC filings. Latest: ARS (Apr 22, 2026). Includes 13 8-K, 6 10-Q, 5 SC 13G/A.
Overview
Cerus Corp (CERS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a ARS filed on Apr 22, 2026: Cerus Corporation filed an Annual Report to Security Holders (ARS) on April 22, 2026, for the period ending December 31, 2025. The filing provides a comprehensive overview of the company's performance and operations for the fiscal year. Cerus Corporation is involved in the Surgical & Medical Instrum
Sentiment Summary
Across 31 filings, the sentiment breakdown is: 29 neutral, 2 mixed. The dominant filing sentiment for Cerus Corp is neutral.
Filing Type Overview
Cerus Corp (CERS) has filed 1 ARS, 2 DEFA14A, 6 10-Q, 13 8-K, 2 DEF 14A, 2 10-K, 5 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (31)
Risk Profile
Risk Assessment: Of CERS's 24 recent filings, 1 were flagged as high-risk, 13 as medium-risk, and 10 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $148.4M |
| Net Income | -$13.4M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $15.7M |
| Operating Margin | N/A |
| Total Assets | $215.2M |
| Total Debt | N/A |
Key Executives
- Dr. William L. Swisher
- Dr. Richard M. Benjamin
- Dr. Michael H. Z. Yu
- Dr. Steven A. Rosen
- Ms. Pamela G. Westbrook
- Mr. Kevin P. McGahren
- Dr. Samuel M. Edelman
- Mr. Kevin J. Kelliher
- Mr. Christopher J. R. Davies
Industry Context
Cerus Corporation operates in the blood safety and transfusion medicine market, a sector focused on improving the safety and efficacy of blood products. Key trends include the increasing demand for pathogen-inactivated blood components and advanced diagnostic tools. The industry is characterized by stringent regulatory oversight and a need for continuous innovation to address evolving infectious disease threats and transfusion-related complications.
Top Tags
medical-devices (4) · 10-Q (4) · financials (4) · sec-filing (3) · Medical Devices (3) · financial-condition (3) · results-of-operations (3) · institutional-ownership (3) · amendment (3) · annual-report (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Product revenue for Q3 2025 | $52.7M | Increased by 14.5% from $46.0M in Q3 2024 |
| Product revenue for nine months 2025 | $148.4M | Increased by 14.6% from $129.5M in nine months 2024 |
| Income from operations for Q3 2025 | $1.2M | Turnaround from a $961K loss in Q3 2024 |
| Net loss attributable to Cerus Corporation for Q3 2025 | $19K | 99.3% reduction from $2.9M in Q3 2024 |
| Net loss attributable to Cerus Corporation for nine months 2025 | $13.4M | 26.9% reduction from $18.4M in nine months 2024 |
| Total assets as of Sep 30, 2025 | $215.2M | Increased from $200.9M at Dec 31, 2024 |
| Cash and cash equivalents as of Sep 30, 2025 | $15.7M | Decreased from $20.3M at Dec 31, 2024 |
| Net cash used in operating activities for nine months 2025 | $1.4M | Shift from $6.4M provided in nine months 2024 |
| Net Loss | $17.5M | Increased from $12.1M in prior-year period, indicating widening losses. |
| Total Revenue | $45.3M | Up 13% from $40.1M in prior-year period, showing top-line growth. |
| Product Revenue | $43.2M | Increased from $38.9M, driven by INTERCEPT Blood System sales. |
| R&D Expenses | $19.8M | Up from $17.2M, primarily due to INTERCEPT Fibrinogen Complex trials. |
| SG&A Expenses | $27.1M | Increased from $24.5M, reflecting higher personnel and commercialization costs. |
| Cash & Equivalents | $75.2M | Decreased from $90.5M at year-end 2024, indicating significant cash burn. |
| Revenue Growth | 13% | Percentage increase in total revenue year-over-year for Q2 2025. |
Forward-Looking Statements
- {"claim":"Vanguard will maintain a significant, passive stake in Cerus Corp.","entity":"The Vanguard Group","targetDate":"Next 12 months","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cerus Corp (CERS)?
Cerus Corp has 31 recent SEC filings from Jan 2024 to Apr 2026, including 13 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CERS filings?
Across 31 filings, the sentiment breakdown is: 29 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Cerus Corp SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cerus Corp (CERS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cerus Corp?
Key financial highlights from Cerus Corp's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CERS?
The investment thesis for CERS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cerus Corp?
Key executives identified across Cerus Corp's filings include Dr. William L. Swisher, Dr. Richard M. Benjamin, Dr. Michael H. Z. Yu, Dr. Steven A. Rosen, Ms. Pamela G. Westbrook and 4 others.
What are the main risk factors for Cerus Corp stock?
Of CERS's 24 assessed filings, 1 were flagged high-risk, 13 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Cerus Corp?
Recent forward-looking statements from Cerus Corp include guidance on {"claim":"Vanguard will maintain a significant, passive stake in Cerus Corp.","entity":"The Vanguard Group","targetDate".